In 2017, the FDA approved 80 drugs with orphan drug designation. GlobalData’s Pharma Intelligence Center database covers the clinical trials for those 80 drugs, including a key analysis of the top 10 drugs with the most clinical trials, by therapy area, trial status, and trial phase.
Orphan drugs in 2017
Clinical trials for the top 10 drugs occupy only three therapy areas, with majority of them in Infectious Disease (70.4%), followed by Oncology (23.8%) and Hormonal Disorders (5.8%) (Figure 1). Also, over 57% of these clinical trials have been completed, with 30.2% ongoing, 7.3% planned, and 5.5% terminated (Figure 2). At least 20% of trials are in each phase between Phase I and Phase IV, while only 0.8% are in Phase 0 (Figure 3).
Go deeper with GlobalData
Figure 1:Top 10 orphan drug designation drugs with most clinical trials, by therapy area
| Source: GlobalData, Pharma Intelligence Center |
Figure 2: Top 10 orphan drug designation drugs with most clinical trials, by trial status
| Source: GlobalData, Pharma Intelligence Center |
Figure 3: Top 10 orphan drug designation drugs with most clinical trials, by trial phase
| Source: GlobalData, Pharma Intelligence Center |
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalData
Related Company Profiles
Oncology, Ltd.